834
Participants
Start Date
March 31, 2011
Primary Completion Date
November 14, 2013
Study Completion Date
April 17, 2014
Sifalimumab 200 mg
Sifalimumab 200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
Sifalimumab 600 mg
Sifalimumab 600 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
Sifalimumab 1,200 mg
Sifalimumab 1,200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
Placebo
IV Placebo every 2 weeks for 4 weeks and then monthly for 44 weeks
Research Site, La Jolla
Research Site, Palm Desert
Research Site, San Leandro
Research Site, Fort Lauderdale
Research Site, Orlando
Research Site, Stockbridge
Research Site, Idaho Falls
Research Site, Shreveport
Research Site, Baltimore
Research Site, Lansing
Research Site, Brooklyn
Research Site, Manhasset
Research Site, New York
Research Site, Charlotte
Research Site, Raleigh
Research Site, Dallas
Research Site, Seattle
Research Site, Buenos Aires
Research Site, Ciudad Autonoma de Buenos Aire
Research Site, Ciudad de Buenos Aires
Research Site, La Plata
Research Site, Quilmes
Research Site, San Miguel de Tucumán
Research Site, Curitiba
Research Site, Goiânia
Research Site, Juiz de Fora
Research Site, Porto Alegre
Research Site, Salvador
Research Site, São Paulo
Research Site, Plovdiv
Research Site, Sofia
Research Site, Québec
Research Site, Sherbrooke
Research Site, Osorno
Research Site, Santiago
Research Site, Viña del Mar
Research Site, Bordeaux
Research Site, Le Kremlin-Bicêtre
Research Site, Paris
Research Site, Strasbourg
Research Site, Berlin
Research Site, Cologne
Research Site, Dresden
Research Site, Frankfurt
Research Site, Kiel
Research Site, Leipzig
Research Site, Mainz
Research Site, Münster
Research Site, Regensburg
Research Site, Würzburg
Research Site, Budapest
Research Site, Debrecen
Research Site, Miskolc
Research Site, Zalaegerszeg
Research Site, Bangalore
Research Site, Secunderabad
Research Site, Brescia
Research Site, Florence
Research Site, Milan
Research Site, Padua
Research Site, Pisa
Research Site, Roma
Research Site, Kingston
Research Site, Chihuahua City
Research Site, Guadalajara
Research Site, México
Research Site, San Luis Potosí City
Research Site, Amsterdam
Research Site, Lima
Research Site, San Borja
Research Site, Cebu City
Research Site, Iloilo City
Research Site, Manila
Research Site, Bialystok
Research Site, Bydgoszcz
Research Site, Katowice
Research Site, Krakow
Research Site, Lublin
Research Site, Olsztyn
Research Site, Poznan
Research Site, Warsaw
Research Site, Brasov
Research Site, Bucharest
Research Site, Cluj-Napoca
Research Site, Tg Mures
Research Site, Cape Town
Research Site, Durban
Research Site, Johannesburg
Research Site, Pinelands
Research Site, Soweto
Research Site, Barcelona
Research Site, Guadalajara
Research Site, La Laguna (Tenerife)
Research Site, Madrid
Research Site, Majadahonda
Research Site, Málaga
Research Site, Mérida
Research Site, Santiago de Compostela
Research Site, Seville
Research Site, Bangkok
Research Site, Brighton
Research Site, Cambridge
Research Site, Cannock
Research Site, Guildford
Research Site, Leeds
Research Site, London
Research Site, Manchester
Lead Sponsor
MedImmune LLC
INDUSTRY